<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 18 Feb 2025 14:10:36 +0000</lastbuilddate>
<pubDate>Tue, 18 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>&lt;em>;TAX1BP3&lt;/em>; Causes TRPV4-Mediated Autosomal Recessive Arrhythmogenic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39963794/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We conclude that TAX1BP3 is associated with rare autosomal recessive ACM through TRPV4-mediated Ca^(2+) leak from RyR2. Further, TRPV4 current inhibition has the potential to be a new therapeutic target for ACM.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 18. doi: 10.1161/CIRCRESAHA.124.325180. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Arrhythmogenic cardiomyopathy (ACM) is one of the leading causes of sudden cardiac death in children, young adults, and athletes and is characterized by the fibro-fatty replacement of the myocardium, predominantly of the right ventricle. Sixty percent of patients with ACM have a known genetic cause, but for the remainder, the etiology is unknown. This lack of mechanistic understanding has also slowed the development of disease-modifying therapies, and children with ACM have a high degree of morbidity and mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Induced pluripotent stem cells (iPSCs) from 3 family members were differentiated into cardiac myocytes (CMs). Calcium imaging was conducted by labeling calcium with CAL-520 and confocal imaging to capture calcium sparks after iPSC-CMs were electrically paced. A cardiac-specific, inducible knockout mouse (Tax1bp3<sup>-/-</sup>) was made and intracardiac electrophysiology studies conducted to observe arrhythmia inducibility following pacing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified a kindred with multiple members affected by ACM cosegregating with biallelic variants in the gene <i>TAX1BP3</i>, which encodes the protein TAX1BP3 (Tax1-binding protein 3). iPSC-CMs derived from this kindred demonstrated increased intracellular lipid droplets, induction of TRPV4 (transient receptor potential vanilloid type 4) expression, and inducible TRPV4 current. This was associated with depletion of the intracellular sarcoplasmic reticulum Ca<sup>2+</sup> store and increased RyR2 (ryanodine receptor 2)-mediated store Ca<sup>2+</sup> leak and delayed afterdepolarizations, a known mechanism of Ca<sup>2+</sup>-mediated arrhythmogenesis. Similarly, Tax1bp3 cardiac-specific knockout mice had increased Ca<sup>2+</sup> leak and were predisposed to ventricular arrhythmias compared with wild-type mice. Ca<sup>2+</sup> leak in both the iPSC-CMs and mouse ventricular myocytes was rescued by small molecule TRPV4 inhibition. This strategy also effectively reduced Ca<sup>2+</sup> leak in a PKP2 (plakophilin 2) p.His773AlafsX8 iPSC-CM model of ACM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We conclude that <i>TAX1BP3</i> is associated with rare autosomal recessive ACM through TRPV4-mediated Ca<sup>2+</sup> leak from RyR2. Further, TRPV4 current inhibition has the potential to be a new therapeutic target for ACM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39963794/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39963794</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325180>10.1161/CIRCRESAHA.124.325180</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39963794</guid>
<pubDate>Tue, 18 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Robin M Perelli</dc:creator>
<dc:creator>Enya R Dewars</dc:creator>
<dc:creator>Heidi Cope</dc:creator>
<dc:creator>Alexander S Behura</dc:creator>
<dc:creator>Anna Q Ponek</dc:creator>
<dc:creator>Angelina M Sala</dc:creator>
<dc:creator>Zhushan Zhang</dc:creator>
<dc:creator>Padmapriya Muralidharan</dc:creator>
<dc:creator>Mary E Moya-Mendez</dc:creator>
<dc:creator>Amy Berkman</dc:creator>
<dc:creator>Gabrielle G Monaco</dc:creator>
<dc:creator>Molly C Sullivan</dc:creator>
<dc:creator>Jordan E Ezekian</dc:creator>
<dc:creator>Qixin Yang</dc:creator>
<dc:creator>Bo Sun</dc:creator>
<dc:creator>Leonie M Kurzlechner</dc:creator>
<dc:creator>Tulsi Asokan</dc:creator>
<dc:creator>Andrew M Breglio</dc:creator>
<dc:creator>M Jay Campbell</dc:creator>
<dc:creator>Zebulon Z Spector</dc:creator>
<dc:creator>Catherine W Rehder</dc:creator>
<dc:creator>Undiagnosed Diseases Network</dc:creator>
<dc:creator>Paul C Tang</dc:creator>
<dc:creator>Cynthia A James</dc:creator>
<dc:creator>Hugh Calkins</dc:creator>
<dc:creator>Vandana Shashi</dc:creator>
<dc:creator>Andrew P Landstrom</dc:creator>
<dc:date>2025-02-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>&lt;em>;TAX1BP3&lt;/em>; Causes TRPV4-Mediated Autosomal Recessive Arrhythmogenic Cardiomyopathy</dc:title>
<dc:identifier>pmid:39963794</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325180</dc:identifier>
</item>
<item>
<title>Multiomic Analysis of Calf Muscle in Peripheral Artery Disease and Chronic Kidney Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39963788/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CKD significantly exacerbates ischemic muscle pathology in PAD, as evidenced by diminished muscle strength, reduced mitochondrial function, and altered transcriptome profiles. The correlation between uremic toxins and muscle dysfunction suggests that targeting these metabolites may offer therapeutic potential for improving muscle health in PAD patients with CKD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 18. doi: 10.1161/CIRCRESAHA.124.325642. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Chronic kidney disease (CKD) has emerged as a significant risk factor that accelerates atherosclerosis, decreases muscle function, and increases the risk of amputation or death in patients with peripheral artery disease (PAD). However, the modulators underlying this exacerbated pathobiology are ill-defined. Recent work has demonstrated that uremic toxins are associated with limb amputation in PAD and have pathological effects in both the limb muscle and vasculature. Herein, we use multiomics to identify novel modulators of disease pathobiology in patients with PAD and CKD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A cross-sectional study enrolled 4 groups of participants: controls without PAD or CKD (n=28), patients with PAD only (n=46), patients with CKD only (n=31), and patients with both PAD and CKD (n=18). Both targeted (uremic toxins) and nontargeted metabolomics in plasma were performed using mass spectrometry. Calf muscle biopsies were used to measure histopathology, perform bulk and single-nucleus RNA sequencing, and assess mitochondrial function. Differential gene and metabolite analyses, as well as pathway and gene set enrichment analyses, were performed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Patients with both PAD and CKD exhibited significantly lower calf muscle strength and smaller muscle fiber areas compared with controls and those with only PAD. Compared with controls, mitochondrial function was impaired in patients with CKD, with or without PAD, but not in PAD patients without CKD. Plasma metabolomics revealed substantial alterations in the metabolome of patients with CKD, with significant correlations observed between uremic toxins (eg, kynurenine and indoxyl sulfate) and both muscle strength and mitochondrial function. RNA sequencing analyses identified downregulation of mitochondrial genes and pathways associated with protein translation in patients with both PAD and CKD. Single-nucleus RNA sequencing further highlighted a mitochondrial deficiency in muscle fibers along with unique remodeling of fibro-adipogenic progenitor cells in patients with both PAD and CKD, with an increase in adipogenic cell populations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CKD significantly exacerbates ischemic muscle pathology in PAD, as evidenced by diminished muscle strength, reduced mitochondrial function, and altered transcriptome profiles. The correlation between uremic toxins and muscle dysfunction suggests that targeting these metabolites may offer therapeutic potential for improving muscle health in PAD patients with CKD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39963788/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39963788</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325642>10.1161/CIRCRESAHA.124.325642</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39963788</guid>
<pubDate>Tue, 18 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Kyoungrae Kim</dc:creator>
<dc:creator>Trace Thome</dc:creator>
<dc:creator>Caroline Pass</dc:creator>
<dc:creator>Lauren Stone</dc:creator>
<dc:creator>Nicholas Vugman</dc:creator>
<dc:creator>Victoria Palzkill</dc:creator>
<dc:creator>Qingping Yang</dc:creator>
<dc:creator>Kerri A O'Malley</dc:creator>
<dc:creator>Erik M Anderson</dc:creator>
<dc:creator>Brian Fazzone</dc:creator>
<dc:creator>Feng Yue</dc:creator>
<dc:creator>Scott A Berceli</dc:creator>
<dc:creator>Salvatore T Scali</dc:creator>
<dc:creator>Terence E Ryan</dc:creator>
<dc:date>2025-02-18</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Multiomic Analysis of Calf Muscle in Peripheral Artery Disease and Chronic Kidney Disease</dc:title>
<dc:identifier>pmid:39963788</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325642</dc:identifier>
</item>
<item>
<title>Sex Chromosomes and Sex Hormones: Dissecting the Forces That Differentiate Female and Male Hearts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>The heart is a highly sex-biased organ, as sex shapes innumerable aspects of heart health and disease. Sex chromosomes and sex hormones -testosterone, progesterone, and estrogen- establish and perpetuate the division between male and female myocardium. Of these differentiating factors, the insulating effects of estrogen have been rigorously interrogated and reviewed, whereas the influence of sex chromosomes, testosterone, and progesterone remains in dispute or ill-defined. Here, we synthesize...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 18;151(7):474-489. doi: 10.1161/CIRCULATIONAHA.124.069493. Epub 2025 Feb 17.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The heart is a highly sex-biased organ, as sex shapes innumerable aspects of heart health and disease. Sex chromosomes and sex hormones -testosterone, progesterone, and estrogen- establish and perpetuate the division between male and female myocardium. Of these differentiating factors, the insulating effects of estrogen have been rigorously interrogated and reviewed, whereas the influence of sex chromosomes, testosterone, and progesterone remains in dispute or ill-defined. Here, we synthesize growing evidence that sex chromosomes and sex hormones substantially bias heart form, function, and dysfunction in a context-dependent fashion. The discrete protective functions ascribed to each of the 3 estrogen receptors are also enumerated. Subsequently, we overview obstacles that have historically discouraged the inclusion of female subjects in basic science such as the impact of the female estrus cycle and reproductive senescence on data reliability and reproducibility. Furthermore, we weigh the utility of several common strategies to intercept and rescue sex-specific protection. Last, we warn of common compounds in animal chow and cell culture that interfere with estrogen signaling. In sum, we survey the controversies and challenges that stem from sex-inclusive cardiovascular research, comparing the possible causes of cardiac sex bias, elucidating sex chromosome or hormone-dependent processes in the heart, describing common lapses that imperil female and male cell and animal work, and illuminating facets of the female heart yet unexplored or still uncertain.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960989</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069493>10.1161/CIRCULATIONAHA.124.069493</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960989</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Annie Brong</dc:creator>
<dc:creator>Aikaterini Kontrogianni-Konstantopoulos</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Sex Chromosomes and Sex Hormones: Dissecting the Forces That Differentiate Female and Male Hearts</dc:title>
<dc:identifier>pmid:39960989</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069493</dc:identifier>
</item>
<item>
<title>Framework for Cultivating Leadership and Driving Growth</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960988/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 18;151(7):430-432. doi: 10.1161/CIRCULATIONAHA.124.073352. Epub 2025 Feb 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960988/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960988</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073352>10.1161/CIRCULATIONAHA.124.073352</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960988</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Francesca Vacante</dc:creator>
<dc:creator>Zehra Yildirim</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Framework for Cultivating Leadership and Driving Growth</dc:title>
<dc:identifier>pmid:39960988</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073352</dc:identifier>
</item>
<item>
<title>Addressing Cardiovascular Health Inequities in Indigenous Women: Insights from Australia and Global Perspectives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960987/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 18;151(7):427-429. doi: 10.1161/CIRCULATIONAHA.124.072828. Epub 2025 Feb 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960987/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960987</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072828>10.1161/CIRCULATIONAHA.124.072828</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960987</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jessy A Nellipudi</dc:creator>
<dc:creator>Bethan Kelly</dc:creator>
<dc:creator>Ashutosh Hardikar</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Addressing Cardiovascular Health Inequities in Indigenous Women: Insights from Australia and Global Perspectives</dc:title>
<dc:identifier>pmid:39960987</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072828</dc:identifier>
</item>
<item>
<title>Population-Level Screening for Diabetes and Dyslipidemia After Pregnancies Complicated by Hypertension or Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 18;151(7):508-510. doi: 10.1161/CIRCULATIONAHA.124.072067. Epub 2025 Feb 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960986</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072067>10.1161/CIRCULATIONAHA.124.072067</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960986</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Amy Y X Yu</dc:creator>
<dc:creator>Nathalie Auger</dc:creator>
<dc:creator>Longdi Fu</dc:creator>
<dc:creator>Anna Chu</dc:creator>
<dc:creator>Moira K Kapral</dc:creator>
<dc:creator>Jodi D Edwards</dc:creator>
<dc:creator>Sonia R Dancey</dc:creator>
<dc:creator>Peter C Austin</dc:creator>
<dc:creator>Manav V Vyas</dc:creator>
<dc:creator>Kara A Nerenberg</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Population-Level Screening for Diabetes and Dyslipidemia After Pregnancies Complicated by Hypertension or Diabetes</dc:title>
<dc:identifier>pmid:39960986</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072067</dc:identifier>
</item>
<item>
<title>Visionary in Structural Heart Disease, Interventional Echocardiography and the Forgotten Valve: A Conversation With Rebecca T. Hahn</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960985/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 18;151(7):436-441. doi: 10.1161/CIRCULATIONAHA.125.072189. Epub 2025 Feb 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960985/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960985</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.072189>10.1161/CIRCULATIONAHA.125.072189</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960985</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Maryjane Farr</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Visionary in Structural Heart Disease, Interventional Echocardiography and the Forgotten Valve: A Conversation With Rebecca T. Hahn</dc:title>
<dc:identifier>pmid:39960985</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.072189</dc:identifier>
</item>
<item>
<title>Ninth Annual Go Red for Women Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960984/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 18;151(7):425-426. doi: 10.1161/CIRCULATIONAHA.125.073852. Epub 2025 Feb 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960984/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960984</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.125.073852>10.1161/CIRCULATIONAHA.125.073852</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960984</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Sana M Al-Khatib</dc:creator>
<dc:creator>Joseph A Hill</dc:creator>
<dc:creator>Mercedes Carnethon</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ninth Annual Go Red for Women Issue</dc:title>
<dc:identifier>pmid:39960984</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.125.073852</dc:identifier>
</item>
<item>
<title>Hypertension in Pregnancy and Postpartum: Current Standards and Opportunities to Improve Care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960983/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>Hypertension in pregnancy contributes substantially to maternal morbidity and mortality, persistent hypertension, and rehospitalization. Hypertensive disorders of pregnancy are also associated with a heightened risk of cardiovascular disease, and timely recognition and modification of associated risk factors is crucial in optimizing long-term maternal health. During pregnancy, there are expected physiologic alterations in blood pressure (BP); however, pathophysiologic alterations may also occur,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 18;151(7):490-507. doi: 10.1161/CIRCULATIONAHA.124.073302. Epub 2025 Feb 17.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hypertension in pregnancy contributes substantially to maternal morbidity and mortality, persistent hypertension, and rehospitalization. Hypertensive disorders of pregnancy are also associated with a heightened risk of cardiovascular disease, and timely recognition and modification of associated risk factors is crucial in optimizing long-term maternal health. During pregnancy, there are expected physiologic alterations in blood pressure (BP); however, pathophysiologic alterations may also occur, leading to preeclampsia and gestational hypertension. The diagnosis and effective management of hypertension during pregnancy is essential to mitigate maternal risks, such as acute kidney injury, stroke, and heart failure, while balancing potential fetal risks, such as growth restriction and preterm birth due to altered uteroplacental perfusion. In the postpartum period, innovative and multidisciplinary care solutions that include postpartum maternal health clinics can help optimize short- and long-term care through enhanced BP management, screening of cardiovascular risk factors, and discussion of lifestyle modifications for cardiovascular disease prevention. As an adjunct to or distinct from postpartum clinics, home BP monitoring programs have been shown to improve BP ascertainment across diverse populations and to lower BP in the months after delivery. Because of concerns about pregnant patients being a vulnerable population for research, there is little evidence from trials examining the diagnosis and treatment of hypertension in pregnant and postpartum individuals. As a result, national and international guidelines differ in their recommendations, and more studies are needed to bolster future guidelines and establish best practices to achieve optimal cardiovascular health during and after pregnancy. Future research should focus on refining treatment thresholds and optimal BP range peripartum and postpartum and evaluating interventions to improve postpartum and long-term maternal cardiovascular outcomes that would advance evidence-based care and improve outcomes worldwide for people with hypertensive disorders of pregnancy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960983/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960983</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073302>10.1161/CIRCULATIONAHA.124.073302</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960983</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Malamo Countouris</dc:creator>
<dc:creator>Zainab Mahmoud</dc:creator>
<dc:creator>Jordana B Cohen</dc:creator>
<dc:creator>Daniela Crousillat</dc:creator>
<dc:creator>Afshan B Hameed</dc:creator>
<dc:creator>Colleen M Harrington</dc:creator>
<dc:creator>Alisse Hauspurg</dc:creator>
<dc:creator>Michael C Honigberg</dc:creator>
<dc:creator>Jennifer Lewey</dc:creator>
<dc:creator>Kathryn Lindley</dc:creator>
<dc:creator>Megan M McLaughlin</dc:creator>
<dc:creator>Neha Sachdev</dc:creator>
<dc:creator>Amy Sarma</dc:creator>
<dc:creator>Kayle Shapero</dc:creator>
<dc:creator>Rachel Sinkey</dc:creator>
<dc:creator>Alan Tita</dc:creator>
<dc:creator>Kristen E Wong</dc:creator>
<dc:creator>Eugene Yang</dc:creator>
<dc:creator>Leslie Cho</dc:creator>
<dc:creator>Natalie A Bello</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Hypertension in Pregnancy and Postpartum: Current Standards and Opportunities to Improve Care</dc:title>
<dc:identifier>pmid:39960983</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073302</dc:identifier>
</item>
<item>
<title>Missing (Black) Women</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960982/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 18;151(7):433-435. doi: 10.1161/CIRCULATIONAHA.124.072699. Epub 2025 Feb 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960982/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960982</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072699>10.1161/CIRCULATIONAHA.124.072699</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960982</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Tené T Lewis</dc:creator>
<dc:creator>Zachary T Martin</dc:creator>
<dc:creator>Jordan E Parker</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Missing (Black) Women</dc:title>
<dc:identifier>pmid:39960982</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072699</dc:identifier>
</item>
<item>
<title>Genes of the Fatty Acid Oxidation Pathway are Upregulated in Female as Compared to Male Cardiomyocytes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960981/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 18;151(7):511-514. doi: 10.1161/CIRCULATIONAHA.124.071973. Epub 2025 Feb 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960981/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960981</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071973>10.1161/CIRCULATIONAHA.124.071973</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960981</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Maya Talukdar</dc:creator>
<dc:creator>Lukáš Chmátal</dc:creator>
<dc:creator>Linyong Mao</dc:creator>
<dc:creator>Daniel Reichart</dc:creator>
<dc:creator>Danielle S Murashige</dc:creator>
<dc:creator>Helen Skaletsky</dc:creator>
<dc:creator>Daniel M DeLaughter</dc:creator>
<dc:creator>Zoltan Arany</dc:creator>
<dc:creator>Jonathan G Seidman</dc:creator>
<dc:creator>Christine E Seidman</dc:creator>
<dc:creator>David C Page</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Genes of the Fatty Acid Oxidation Pathway are Upregulated in Female as Compared to Male Cardiomyocytes</dc:title>
<dc:identifier>pmid:39960981</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071973</dc:identifier>
</item>
<item>
<title>Go Red for Women at 20 Years: Where Do We Go From Here?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960980/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 18;151(7):e39-e40. doi: 10.1161/CIRCULATIONAHA.124.073637. Epub 2025 Feb 17.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960980/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960980</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.073637>10.1161/CIRCULATIONAHA.124.073637</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960980</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Keith Churchwell</dc:creator>
<dc:creator>Stacey E Rosen</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Go Red for Women at 20 Years: Where Do We Go From Here?</dc:title>
<dc:identifier>pmid:39960980</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.073637</dc:identifier>
</item>
<item>
<title>Clarification on methodology used in the study investigating COVID-19 vaccination and cardiovascular events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960846/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 17:ehaf063. doi: 10.1093/eurheartj/ehaf063. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960846/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960846</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf063>10.1093/eurheartj/ehaf063</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960846</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yiyi Xu</dc:creator>
<dc:creator>Fredrik Nyberg</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Clarification on methodology used in the study investigating COVID-19 vaccination and cardiovascular events</dc:title>
<dc:identifier>pmid:39960846</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf063</dc:identifier>
</item>
<item>
<title>COVID-19 vaccinations in adults and evaluation of cardiovascular events: critical methodological issues</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39960844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 17:ehaf061. doi: 10.1093/eurheartj/ehaf061. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39960844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39960844</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf061>10.1093/eurheartj/ehaf061</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39960844</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Serafino Fazio</dc:creator>
<dc:creator>Elisabetta Zanolin</dc:creator>
<dc:creator>Paolo Bellavite</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>COVID-19 vaccinations in adults and evaluation of cardiovascular events: critical methodological issues</dc:title>
<dc:identifier>pmid:39960844</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf061</dc:identifier>
</item>
<item>
<title>β-Hydroxybutyrate Facilitates Postinfarction Cardiac Repair via Targeting PHD2</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39957619/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These data reveal a novel regulation of lysine β-hydroxybutyrylation on PHD2 and demonstrate a promising and therapeutic role for β-OHB/PHD2 in effectively accelerating neovascularization and preserving heart function after cardiac ischemia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 17. doi: 10.1161/CIRCRESAHA.124.325179. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Acute myocardial infarction (MI) remains one of the major causes of death worldwide, and innovative treatment strategies for MI represent a major challenge in cardiovascular medicine. Caloric restriction (CR) is the most potent nonpharmacological intervention known to prevent age-related disorders and extend lifespan. CR reduces glycolysis and elevates ketone body metabolism. However, whether and how CR or ketone body prevents the progression of MI remains poorly defined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Mice treated with CR and β-hydroxybutyrate (β-OHB) underwent MI induced by ligation of the left anterior descending coronary artery. Cardiac function was assessed by echocardiographic measurements. Histological analysis, fluorescence-activated cell sorting, and immunofluorescence were used to assess myocardial neovascularization and macrophage filtration. The interaction and modification of β-OHB on PHD2 were analyzed by molecular docking, cellular thermal shift assay, liquid chromatography with tandem mass spectrometry, and coimmunoprecipitation. Macrophage-specific PHD2 K239R and K385R knock-in mice were used to determine the functional significance of β-OHB/PHD2 axis in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Twelve weeks of CR markedly rescued postinfarction cardiac function by enhancing neovascularization. CR significantly increased circulating and cardiac ketone bodies, including β-OHB and acetoacetate. We identified β-OHB but not acetoacetate selectively targeted macrophages to stimulate VEGF (vascular endothelial growth factor) production in the peri-infarct area to promote neovascularization and cardiac repair. Mechanistically, β-OHB binds to and induces lysine β-hydroxybutyrylation of PHD2 at lysines 239 and 385, thus blocking its function in the hydroxylation of HIF-1α (hypoxia-inducible factor 1α) and resulting in enhanced HIF1α-dependent VEGF transcription and secretion. More importantly, specific PHD2 lys239 and lys385 mutations in macrophages abolished the preventive effects of exogenous β-OHB on MI in mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These data reveal a novel regulation of lysine β-hydroxybutyrylation on PHD2 and demonstrate a promising and therapeutic role for β-OHB/PHD2 in effectively accelerating neovascularization and preserving heart function after cardiac ischemia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39957619/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39957619</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325179>10.1161/CIRCRESAHA.124.325179</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39957619</guid>
<pubDate>Mon, 17 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Cheng Wang</dc:creator>
<dc:creator>Wenjing Xu</dc:creator>
<dc:creator>Shushu Jiang</dc:creator>
<dc:creator>Yichen Wu</dc:creator>
<dc:creator>Jiangchen Shu</dc:creator>
<dc:creator>Xinyuan Gao</dc:creator>
<dc:creator>Kai Huang</dc:creator>
<dc:date>2025-02-17</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>β-Hydroxybutyrate Facilitates Postinfarction Cardiac Repair via Targeting PHD2</dc:title>
<dc:identifier>pmid:39957619</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325179</dc:identifier>
</item>
<item>
<title>Mammary intraepithelial lymphocytes promote lactogenesis and offspring fitness</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39954680/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>Breastfeeding is an obligatory requirement of mammalian survival. This fundamental process is associated with the adaptation of maternal physiology, including the transformation of the mammary gland into a milk-secreting organ. How maternal immunity contributes to mammary gland remodeling and function remains largely unknown. Here, we show that maternal adaptive immunity plays a critical role in shaping lactogenesis. Specifically, physiological adaptation during pregnancy is associated with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 11:S0092-8674(25)00097-2. doi: 10.1016/j.cell.2025.01.028. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Breastfeeding is an obligatory requirement of mammalian survival. This fundamental process is associated with the adaptation of maternal physiology, including the transformation of the mammary gland into a milk-secreting organ. How maternal immunity contributes to mammary gland remodeling and function remains largely unknown. Here, we show that maternal adaptive immunity plays a critical role in shaping lactogenesis. Specifically, physiological adaptation during pregnancy is associated with thymic involution and a paradoxical enrichment in intraepithelial lymphocyte (IEL) precursors that no longer migrate to the gut but instead preferentially accumulate within the mammary gland. IEL precursors differentiate into T-bet-expressing unconventional CD8αα lymphocytes in an IL-15-dependent manner. Mammary IELs control milk production by favoring the differentiation and maturation of contractile and milk-secreting cells, thereby promoting offspring fitness. Altogether, this work uncovers a contribution of the maternal adaptive immune system in organismal remodeling during pregnancy that is associated with mammary gland development and function.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39954680/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39954680</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.028>10.1016/j.cell.2025.01.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39954680</guid>
<pubDate>Sat, 15 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Dan Corral</dc:creator>
<dc:creator>Eduard Ansaldo</dc:creator>
<dc:creator>Jérémie Delaleu</dc:creator>
<dc:creator>Andrea C Pichler</dc:creator>
<dc:creator>Juraj Kabat</dc:creator>
<dc:creator>Cihan Oguz</dc:creator>
<dc:creator>Ana Teijeiro</dc:creator>
<dc:creator>Daniel Yong</dc:creator>
<dc:creator>Mahnoor Abid</dc:creator>
<dc:creator>Claudia A Rivera</dc:creator>
<dc:creator>Verena M Link</dc:creator>
<dc:creator>Katharine Yang</dc:creator>
<dc:creator>Liang Chi</dc:creator>
<dc:creator>Jia Nie</dc:creator>
<dc:creator>Olena Kamenyeva</dc:creator>
<dc:creator>Yiping Fan</dc:creator>
<dc:creator>Jerry Kok Yen Chan</dc:creator>
<dc:creator>Florent Ginhoux</dc:creator>
<dc:creator>Rémy Bosselut</dc:creator>
<dc:creator>Yasmine Belkaid</dc:creator>
<dc:date>2025-02-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mammary intraepithelial lymphocytes promote lactogenesis and offspring fitness</dc:title>
<dc:identifier>pmid:39954680</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.028</dc:identifier>
</item>
<item>
<title>Male-male interactions shape mate selection in Drosophila</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39952248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>Males of many species have evolved behavioral traits to both attract females and repel rivals. Here, we explore mate selection in Drosophila from both the male and female perspective to shed light on how these key components of sexual selection-female choice and male-male competition-work in concert to guide reproductive strategies. We find that male flies fend off competing suitors by interleaving their courtship of a female with aggressive wing flicks, which both repel competitors and generate...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 11:S0092-8674(25)00037-6. doi: 10.1016/j.cell.2025.01.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Males of many species have evolved behavioral traits to both attract females and repel rivals. Here, we explore mate selection in Drosophila from both the male and female perspective to shed light on how these key components of sexual selection-female choice and male-male competition-work in concert to guide reproductive strategies. We find that male flies fend off competing suitors by interleaving their courtship of a female with aggressive wing flicks, which both repel competitors and generate a "song" that obscures the female's auditory perception of other potential mates. Two higher-order circuit nodes-P1a and pC1x neurons-are coordinately recruited to allow males to flexibly interleave these agonistic actions with courtship displays, assuring they persistently pursue females until their rival falters. Together, our results suggest that female mating decisions are shaped by male-male interactions, underscoring how a male's ability to subvert his rivals is central to his reproductive success.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39952248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39952248</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.008>10.1016/j.cell.2025.01.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39952248</guid>
<pubDate>Fri, 14 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Tom Hindmarsh Sten</dc:creator>
<dc:creator>Rufei Li</dc:creator>
<dc:creator>Florian Hollunder</dc:creator>
<dc:creator>Shade Eleazer</dc:creator>
<dc:creator>Vanessa Ruta</dc:creator>
<dc:date>2025-02-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Male-male interactions shape mate selection in Drosophila</dc:title>
<dc:identifier>pmid:39952248</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.008</dc:identifier>
</item>
<item>
<title>Synonymous mutations promote tumorigenesis by disrupting m&lt;sup>;6&lt;/sup>;A-dependent mRNA metabolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39952247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>Cancer cells acquire numerous mutations during tumorigenesis, including synonymous mutations that do not change the amino acid sequence of a protein. RNA N6-methyladenosine (m⁶A) is a post-transcriptional modification that plays critical roles in oncogenesis. Herein, we identified 12,849 mutations in the cancer genome with the potential to perturb m⁶A modification patterns, which we refer to as "m⁶A disruption mutations (m⁶A-DMs)." These are either synonymous m⁶A-DMs (sm⁶A-DMs) or missense...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 11:S0092-8674(25)00095-9. doi: 10.1016/j.cell.2025.01.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cancer cells acquire numerous mutations during tumorigenesis, including synonymous mutations that do not change the amino acid sequence of a protein. RNA N6-methyladenosine (m<sup>6</sup>A) is a post-transcriptional modification that plays critical roles in oncogenesis. Herein, we identified 12,849 mutations in the cancer genome with the potential to perturb m<sup>6</sup>A modification patterns, which we refer to as "m<sup>6</sup>A disruption mutations (m<sup>6</sup>A-DMs)." These are either synonymous m<sup>6</sup>A-DMs (sm<sup>6</sup>A-DMs) or missense m<sup>6</sup>A-DMs (mm<sup>6</sup>A-DMs) mutations, and the former is enriched within tumor suppressor genes, such as CDKN2A and BRCA2. Using epitranscriptomic editing, we demonstrate that manipulating m<sup>6</sup>A levels at specific sm<sup>6</sup>A-DM sites influences mRNA stability. Furthermore, introducing CDKN2A sm<sup>6</sup>A-DMs into cancer cells promotes tumor growth while BRCA2 sm<sup>6</sup>A-DMs sensitize tumors to the poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. Our findings demonstrate sm<sup>6</sup>A-DMs as potential oncogenic drivers, unveiling implications for synonymous mutations in tumorigenesis and beyond.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39952247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39952247</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.026>10.1016/j.cell.2025.01.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39952247</guid>
<pubDate>Fri, 14 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yiheng Lan</dc:creator>
<dc:creator>Zhen Xia</dc:creator>
<dc:creator>Qizhe Shao</dc:creator>
<dc:creator>Peng Lin</dc:creator>
<dc:creator>Jinhong Lu</dc:creator>
<dc:creator>Xiaoying Xiao</dc:creator>
<dc:creator>Mengyue Zheng</dc:creator>
<dc:creator>Di Chen</dc:creator>
<dc:creator>Yanmei Dou</dc:creator>
<dc:creator>Qi Xie</dc:creator>
<dc:date>2025-02-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Synonymous mutations promote tumorigenesis by disrupting m&lt;sup>;6&lt;/sup>;A-dependent mRNA metabolism</dc:title>
<dc:identifier>pmid:39952247</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.026</dc:identifier>
</item>
<item>
<title>Design of CoQ&lt;sub>;10&lt;/sub>; crops based on evolutionary history</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39952246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>Coenzyme Q (CoQ) is essential for energy production by mitochondrial respiration, and it is a supplement most often used to promote cardiovascular health. Humans make CoQ(10), but cereals and some vegetable/fruit crops synthesize CoQ(9) with a side chain of nine isoprene units. Engineering CoQ(10) production in crops would benefit human health, but this is hindered by the fact that the specific residues of the enzyme Coq1 that control chain length are unknown. Based on an extensive investigation...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 11:S0092-8674(25)00087-X. doi: 10.1016/j.cell.2025.01.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Coenzyme Q (CoQ) is essential for energy production by mitochondrial respiration, and it is a supplement most often used to promote cardiovascular health. Humans make CoQ<sub>10</sub>, but cereals and some vegetable/fruit crops synthesize CoQ<sub>9</sub> with a side chain of nine isoprene units. Engineering CoQ<sub>10</sub> production in crops would benefit human health, but this is hindered by the fact that the specific residues of the enzyme Coq1 that control chain length are unknown. Based on an extensive investigation of the distribution of CoQ<sub>9</sub> and CoQ<sub>10</sub> in land plants and the associated Coq1 sequence variation, we identified key amino acid changes at the base of the Coq1 catalytic pocket that occurred independently in multiple angiosperm lineages and repeatedly drove CoQ<sub>9</sub> formation. Guided by this knowledge, we used gene editing to modify the native Coq1 genes of rice and wheat to produce CoQ<sub>10</sub>, paving the way for developing additional dietary sources of CoQ<sub>10</sub>.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39952246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39952246</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.023>10.1016/j.cell.2025.01.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39952246</guid>
<pubDate>Fri, 14 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Jing-Jing Xu</dc:creator>
<dc:creator>Yuan Lei</dc:creator>
<dc:creator>Xiao-Fan Zhang</dc:creator>
<dc:creator>Jian-Xu Li</dc:creator>
<dc:creator>Qiupeng Lin</dc:creator>
<dc:creator>Xiang-Dong Wu</dc:creator>
<dc:creator>Yu-Guo Jiang</dc:creator>
<dc:creator>Wenyi Zhang</dc:creator>
<dc:creator>Runtong Qian</dc:creator>
<dc:creator>Shu-Yi Xiong</dc:creator>
<dc:creator>Kuo Tan</dc:creator>
<dc:creator>Yu Jia</dc:creator>
<dc:creator>Qiang Zhou</dc:creator>
<dc:creator>Yan Jiang</dc:creator>
<dc:creator>Hang Fan</dc:creator>
<dc:creator>Yan-Bo Huang</dc:creator>
<dc:creator>Ling-Jian Wang</dc:creator>
<dc:creator>Ji-Yun Liu</dc:creator>
<dc:creator>Yu Kong</dc:creator>
<dc:creator>Qing Zhao</dc:creator>
<dc:creator>Lei Yang</dc:creator>
<dc:creator>Jinxing Liu</dc:creator>
<dc:creator>Yong-Hong Hu</dc:creator>
<dc:creator>Shuai Zhan</dc:creator>
<dc:creator>Caixia Gao</dc:creator>
<dc:creator>Xiao-Ya Chen</dc:creator>
<dc:date>2025-02-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Design of CoQ&lt;sub>;10&lt;/sub>; crops based on evolutionary history</dc:title>
<dc:identifier>pmid:39952246</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.023</dc:identifier>
</item>
<item>
<title>Current status of aortic valve repair surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39950993/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>Severe aortic valve regurgitation, if not timely treated, can significantly impact patients' survival both for tricuspid aortic valve and bicuspid aortic valve patients, with the latter being significantly younger. Increased understanding of the root anatomy and its physiology has opened the way to techniques of aortic valve repair surgery. The techniques mainly relate to re-establishing a correct root and annular geometry and eliminating leaflet prolapse. These techniques are applied both in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 14:ehaf038. doi: 10.1093/eurheartj/ehaf038. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Severe aortic valve regurgitation, if not timely treated, can significantly impact patients' survival both for tricuspid aortic valve and bicuspid aortic valve patients, with the latter being significantly younger. Increased understanding of the root anatomy and its physiology has opened the way to techniques of aortic valve repair surgery. The techniques mainly relate to re-establishing a correct root and annular geometry and eliminating leaflet prolapse. These techniques are applied both in the presence of a dilated and normal root and are equally valid for tricuspid or bicuspid valve. Techniques for repairing a bicuspid valve might vary depending on the different valve phenotypes. Medium and long-term results appear favourable and potentially superior to those of prosthetic replacement in terms of valve-related complications and quality of life. Optimal surgical treatment, especially in younger and selected patients, should aim to avoid aortic valve replacement and its related complications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39950993/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39950993</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf038>10.1093/eurheartj/ehaf038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39950993</guid>
<pubDate>Fri, 14 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Ruggero De Paulis</dc:creator>
<dc:creator>Ilaria Chirichilli</dc:creator>
<dc:creator>Laurent de Kerchove</dc:creator>
<dc:creator>Alessandro Della Corte</dc:creator>
<dc:creator>Gebrine El Khoury</dc:creator>
<dc:creator>Hector I Michelena</dc:creator>
<dc:creator>Andrea Salica</dc:creator>
<dc:creator>Hans-Joachim Schäfers</dc:creator>
<dc:date>2025-02-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Current status of aortic valve repair surgery</dc:title>
<dc:identifier>pmid:39950993</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf038</dc:identifier>
</item>
<item>
<title>Expanding the triglyceride range in clinical trials: therapeutic opportunities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39950981/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250218091035&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Individuals with mild-to-moderate hypertriglyceridaemia may not express the same magnitude of cardiovascular risk as that observed across the full range of plasma triglycerides. Future triglyceride-lowering therapy trials may want to consider enrolment across a wider range of triglyceride levels if there is no prior history of pancreatitis nor excessive alcohol intake.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 14:ehaf074. doi: 10.1093/eurheartj/ehaf074. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Guidelines focus on individuals with triglycerides between 2.3 and 5.6 mmol/L (200 and 499 mg/dL). The hypotheses that triglycerides across the full biological range and within this constrained range associated with cardiovascular risk were re-assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Multivariable-adjusted hazard ratios for major cardiovascular events and death according to baseline triglycerides among 119 573 individuals with triglycerides across the full biological range from the Copenhagen General Population Study, among 27 757 individuals with baseline triglycerides between 2.3 and 5.6 mmol/L from the Copenhagen General Population Study and the Women's Health Study cohorts, and among 31 272 individuals with mild-to-moderate hypertriglyceridaemia from the PROMINENT, REDUCE-IT, and STRENGTH trials were calculated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Increasing triglycerides across the full range (0.3 to 11.2 mmol/L) were associated with an increasing risk of major cardiovascular events (N = 12 241). In the cohorts, combined hazard ratios [95% confidence interval (triglyceride range in mmol/L)] for major cardiovascular events (N = 3928) from lowest to highest triglyceride quartile were 1.0 [referent (range: &lt; 2.5)], 0.95 [0.87-1.04 (range: 2.5 to &lt;3.0)], 1.04 [0.95-1.13 (range: 3.0 to &lt;3.6)], and 1.13 [1.04-1.23 (range: ≥ 3.6)]. In the three contemporary trials, the corresponding hazard ratios (N = 4265 cardiovascular events) from lowest to highest quartile were 1.0 [referent (ranges for PROMINENT/REDUCE-IT/STRENGTH: &lt; 2.6/2.0/2.2)], 1.01 [0.93-1.10 (ranges: 2.6 to &lt;3.1/2.0 to &lt;2.5/2.2 to &lt;2.7)], 1.05 [0.96-1.14 (ranges: 3.1 to &lt;3.9/2.5 to &lt;3.1/2.7 to &lt; 3.5)] and 1.09 [1.00-1.19 (ranges: ≥ 3.9/3.1/3.5)]. In neither cohorts nor trials were triglycerides across this range strongly associated with risk of cardiovascular or all-cause death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Individuals with mild-to-moderate hypertriglyceridaemia may not express the same magnitude of cardiovascular risk as that observed across the full range of plasma triglycerides. Future triglyceride-lowering therapy trials may want to consider enrolment across a wider range of triglyceride levels if there is no prior history of pancreatitis nor excessive alcohol intake.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39950981/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250218091035&v=2.18.0.post9+e462414">39950981</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf074>10.1093/eurheartj/ehaf074</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39950981</guid>
<pubDate>Fri, 14 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Ask T Nordestgaard</dc:creator>
<dc:creator>Aruna D Pradhan</dc:creator>
<dc:creator>Brendan M Everett</dc:creator>
<dc:creator>Jean G MacFadyen</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Frank L J Visseren</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Raul D Santos</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:creator>Børge G Nordestgaard</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:date>2025-02-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Expanding the triglyceride range in clinical trials: therapeutic opportunities</dc:title>
<dc:identifier>pmid:39950981</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf074</dc:identifier>
</item>





























</channel>
</rss>